The Path of EMD-101: From R&D to IND

Time: 1:15 pm
day: Day 2 Track B PM

Details:

• Delving into the key hurdles in establishing proof of safety and efficacy ahead of an IND application
• Understanding the nuances of the IND application itself, and where the potential regulatory objections may arise
• Exploring the required CMC information needed by regulatory bodies

Speakers:

Tamar Auerbach-Nevo VP of Development at Emendo Bio with over 15 years of experience in multiple and diverse biotech companies. Leading the development of EMD-101 for indicated Read more